Celularity INC

Celularity Inc. has entered into a $1 million loan agreement with a trust affiliated with a major shareholder and announced the resignation of a board member.

Celularity Inc. has appointed Steven N. Gordon as Chief Operating and Administrative Officer and Director, and K. Harold Fletcher as Chief Legal and Strategy Officer.

Celularity Inc. has been notified by Nasdaq that its market value of listed securities has fallen below the required $35 million threshold.

Celularity Inc. announced the appointment of Rick Gonzalez as Chief Commercial Officer to drive commercialization of its placental-derived cell therapies, including cenplacel-L and its Lifebank platform, supporting its strategic focus on longevity and regenerative medicine.

Celularity Inc. has entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd. to resolve outstanding claims and restructure existing debt obligations.

Celularity Inc. announced an amendment to its asset purchase and license agreement with NexGel, Inc., receiving $13.3 million and potential future milestones, while also addressing a default notice from Helena regarding a convertible note.

Celularity Inc. reported a significant increase in net losses and a substantial doubt about its ability to continue as a going concern, driven by declining product sales and ongoing operational expenditures.

Celularity Inc. reported significant losses and a going concern warning for Q2 2025, alongside Nasdaq delisting threats and multiple legal challenges.

Celularity Inc. reported a significant revenue decline and increased operating losses in Q1 2025, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice.

Celularity Inc. reports a significant increase in revenue for the third quarter of 2024, but continues to face substantial financial challenges and going concern uncertainties.

Celularity Inc. reported a significant increase in revenue for the second quarter of 2024, driven by its degenerative disease segment, but faces substantial financial challenges and uncertainties about its ability to continue as a going concern.

Celularity Inc. released its first quarter 2024 results, highlighting increased product sales but also significant operating losses and ongoing financial uncertainties.

Celularity Inc. files an amendment to its 2024 annual report on Form 10-K/A, focusing on Part III disclosures related to directors, executive officers, compensation, and corporate governance.

Celularity Inc.'s fiscal year 2024 results reveal a net loss and substantial doubt about its ability to continue as a going concern, despite increased revenues.

Celularity Inc.'s annual 10-K filing highlights significant net losses, substantial debt, and a strategic pipeline refocus, raising concerns about its ability to continue as a going concern.

Stephen Brigido, President of Functional Regeneration at Celularity Inc., reported the vesting of restricted stock units and a subsequent tax-related share disposition.

Senior Executive Vice President John Haines acquired 1,641 shares of Celularity Inc. through the vesting of restricted stock units.

Celularity Inc. CEO Robert J. Hariri acquired 3,281 shares of Class A Common Stock through the vesting of restricted stock units.

Celularity Inc. Director Diane L. Parks acquired 30,000 shares of Class A common stock through an RSU grant, increasing her beneficial ownership to 520,021 shares.

Celularity Inc. Director Peter Diamandis reported an amended acquisition of 20,385 Class A common stock shares through immediately vesting restricted stock units.

Celularity Inc. Director Geoffrey Ling, M.D., reported the acquisition of 19,231 Class A common stock shares through immediately vesting restricted stock units.

Celularity Inc. has filed a definitive proxy statement with the SEC under Schedule 14A.

Celularity Inc. announces its 2025 Annual Meeting of Stockholders to elect Class I directors, ratify its independent auditor, and approve an increase of 3.5 million shares for its 2021 Equity Incentive Plan.

Celularity Inc. will hold its 2024 Annual Meeting of Stockholders on December 19, 2024, to elect a Class III director and ratify the appointment of its independent auditor.

Celularity Inc. filed an S-1 registration statement for the resale of up to 14,078,938 Class A Common Stock by selling stockholders, while facing substantial doubt about its ability to continue as a going concern.

Celularity Inc. filed an S-1 registration statement for the resale of up to 15.9 million Class A Common Stock shares by existing stockholders, while disclosing substantial doubt about its ability to continue as a going concern.

Celularity Inc. announces a proposed public offering of Class A common stock and pre-funded warrants to raise capital.

Celularity Inc. announces a public offering of up to 6,521,739 shares of Class A common stock and pre-funded warrants to raise capital for working capital and general corporate purposes.

Philip & Daniele Barach Family Trust amends Schedule 13D, reporting 20.1% beneficial ownership of Celularity Inc. Class A Common Stock following financing.

The Philip & Daniele Barach Family Trust has reported beneficial ownership of 9.56% of Celularity Inc.'s Class A Common Stock following a significant financing arrangement.

Celularity Inc. has amended existing loan agreements and issued new warrants and a promissory note to affiliates of Genting Berhad and Lim Kok Thay, extending debt maturities and adjusting warrant exercise prices.

Dragasac Limited, a key investor in Celularity Inc., has significantly increased its beneficial ownership to 26.8% by exercising warrants at a discounted price, injecting nearly $2.5 million into the company.

Lincoln Alternative Strategies LLC has filed an amended Schedule 13G, indicating it no longer holds a beneficial ownership stake in Celularity Inc.

Lincoln Alternative Strategies LLC has reported a 5.14% beneficial ownership stake in Celularity Inc.'s Class A Common Stock.

Bristol Myers Squibb Company and its subsidiary Celgene Corporation have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 1.9% in Celularity Inc.'s Class A Common Stock.